Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex neurodegenerative condition caused by multiple factors. Researchers from the Gladstone Institutes and the University of California, San Francisco (UCSF) have screened FDA-approved drugs in search of agents that could potentially modify the disease. Read More
Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by systemic inflammation and progressive joint destruction. Current treatments include conventional disease-modifying antirheumatic drugs and biologics. However, long-term treatment is frequently associated with drug resistance and significant adverse effects. Read More
Nextcure Inc. has unveiled new preclinical data supporting the therapeutic potential of NC-605, a new anti-Siglec-15 antibody, in treating osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones and frequent fractures.
Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked to a number of inflammatory diseases. Matchpoint’s approach leverages the properties of covalent chemistry and a proprietary platform to target a novel binding site on a historically hard-to-drug protein. Read More
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe respiratory conditions characterized by complex and incompletely understood pathophysiological mechanisms. Increasing evidence suggests that mitochondrial dysfunction contributes significantly to ALI pathogenesis. Read More
Congruence Therapeutics Inc. has received a research grant of $5 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its GCase-targeting small molecules for GBA1 Parkinson’s disease. Mutations of the GBA1 gene, encoding the enzyme GCase, represent the single largest genetic risk factor for Parkinson’s disease. Read More
Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and commercialize molecular gate therapeutics. The collaboration will leverage Gate’s molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-to-drug proteins. Read More
Dewpoint Therapeutics Inc. has described TAR DNA-binding protein 43 (TARDBP; TDP-43) modulators reported to be useful for the treatment of traumatic brain injury, frontotemporal dementia and amyotrophic lateral sclerosis. Read More
Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, osteosarcoma, glaucoma, ocular hypertension, dry eye, uveitis and age-related macular degeneration, among others. Read More
Stroke is the third leading cause of disability worldwide, and its incidence is expected to increase as the global population ages. Idebenone can promote recovery after stroke, but it is less effective during the acute phase of stroke. Read More
Cytosinlab Therapeutics Co. Ltd. has synthesized G/T mismatch-specific thymine DNA glycosylase (TDG) inhibitors reported to be useful for the treatment of cancer. Read More
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer. Read More
Ischemic retinopathy refers to a group of ocular disorders characterized by insufficient retinal blood flow, leading to hypoxia and subsequent retinal tissue damage. In the hypoxic environment, hypoxia-inducible factor 1α (HIF-1α) activates the transcription of pro-angiogenic factors that promote pathological retinal neovascularization, which ultimately contributes to edema, retinal damage and vision loss. Read More
Beijing Innocare Pharma Tech Co. Ltd. has patented molecular glue degrader compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, inflammation, neurodegenerative and dermatological disorders. Read More
